Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines-Reference-Cited by-同舟云学术

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

Published:2022-06-01 Issue:1 Volume:61 Page:
ISSN:1019-6439
Container-title:International Journal of Oncology
language:
Short-container-title:Int J Oncol

Author:

Fedier André¹,Maggi Nadia¹,Tozzi Alessandra²,Disler Muriel¹,Coelho Ricardo¹,Jacob Francis¹,Heinzelmann‑schwarz Viola¹

Affiliation:

1. Ovarian Cancer Research Program, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland

2. Hospital for Women, Department of Gynecology and Gynecological Oncology, Women's Hospital, University Hospital Basel, University of Basel, 4021 Basel, Switzerland

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference58 articles.

1. Molecular mechanisms of drug resistance;Longley;J Pathol,2005

2. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications;Shibue;Nat Rev Clin Oncol,2017

3. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature,2005

4. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

5. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition;McCabe;Cancer Res,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates;Bioorganic Chemistry;2023-09

2. Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer;Cancers;2023-07-25

3. Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer;Cell Death & Disease;2022-10-28